SCHEMBL2437888

SCHEMBL2437888

COC(=O)c1ccc(OC[C@@H]2CCCN2CC(=O)OC(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.46
KDM4E B2RXH2 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
CASP3 P42574 1/20 0.43
MAPT P10636 1/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC1 Q13547 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA5 P30532 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432680 0.83 KDM4E (0.43) KDM4ECASP3MAPTCHRNB2CHRNA5
SCHEMBL2434344 0.83 KDM4E (0.43) KDM4ECASP3MAPTCHRNB2CHRNA5
SCHEMBL4314893 0.83 LTA4H (0.68) LTA4HCASP3CHRNB2
SCHEMBL4314887 0.83 LTA4H (0.68) LTA4HCASP3CHRNB2
SCHEMBL5151622 0.83 NPC1 (0.47) KDM4EMAPT
SCHEMBL4320519 0.82 LTA4H (0.50) LTA4HHRH3CASP3CHRNB2CHRNA5
SCHEMBL4320524 0.82 LTA4H (0.50) LTA4HHRH3CASP3CHRNB2CHRNA5
SCHEMBL2438025 0.82 CHRNB2 (0.57) LTA4HKDM4EMAPTCHRNB2CHRNA5
SCHEMBL4316696 0.80 LTA4H (0.73) LTA4HCASP3
SCHEMBL4316703 0.80 LTA4H (0.73) LTA4HCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 LTA4H 13/4885KDM4E 1271/4885HRH3 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.